Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

Minkyu Jung; Ja Seung Koo; Young Wha Moon; Byeong-Woo Park; Seung Il Kim; Seho Park; Soo Hyun Lee; Soojung Hong; Sun Young Rha; Hyun Cheol Chung; Joo Hang Kim; Joohyuk Sohn

doi:10.1371/journal.pone.0045127

Loading metrics

Open Access

Peer-reviewed

Research Article

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

Minkyu Jung,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Ja Seung Koo,

Affiliation Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
⨯
Young Wha Moon,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Byeong-Woo Park,

Affiliation Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
⨯
Seung Il Kim,

Affiliation Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
⨯
Seho Park,

Affiliation Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
⨯
Soo Hyun Lee,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Soojung Hong,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Sun Young Rha,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Hyun Cheol Chung,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Joo Hang Kim,

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯
Joohyuk Sohn

* E-mail: oncosohn@yuhs.ac

Affiliation Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
⨯

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

Minkyu Jung,
Ja Seung Koo,
Young Wha Moon,
Byeong-Woo Park,
Seung Il Kim,
Seho Park,
Soo Hyun Lee,
Soojung Hong,
Sun Young Rha,
Hyun Cheol Chung

Published: September 20, 2012
https://doi.org/10.1371/journal.pone.0045127

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Fluorescent in situ hybridization
Is the Subject Area "Fluorescent in situ hybridization" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Immune receptors
Is the Subject Area "Immune receptors" applicable to this article?

Thanks for your feedback.
Ovarian cancer
Is the Subject Area "Ovarian cancer" applicable to this article?

Thanks for your feedback.
Brain metastasis
Is the Subject Area "Brain metastasis" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.